COVID Vaccines are here, with multiple approved versions, and many more in development. In this episode, Lizanne Falsetto (YPO Pacific Coast Gold) addresses immediate and timely questions to educate and alleviate concerns with Immunology Expert, Michael Julius, to help us cut through all the noise about the vaccine and what to expect.

About Michael Julius, PhD

Michael is past Vice President, Research at Sunnybrook Health Sciences Centre (2000-2020). He created an international hub for life sciences dedicated to both discovery and commercialization. This initiative achieved afunctional integration of researchers, clinicians, business, and patients towards moving discoveries into the clinic. He shepherded growth to a $125M annual research enterprise which spun off 15 companies over his tenure. Michaelis currently partnering in the launch of a life sciences capital management fund. Ahead of taking on his leadership position at Sunnybrook, Michael Chaired the Department of Immunology at the University of Toronto (1994-2000), and as of 2020 is professor emeritus in the Department. He has chaired both the Canadian Institutes for Health Research review panel for Immunology and Transplantation and Research Canada, an advocacy corporation dedicated to ensuring that the federal government supports and funds the priority of health research in Canada. He serves as a member of Scientific Advisory Boards for a number of companies and has Chaired two of Sunnybrook’s spin-off companies. Michael completed his undergraduate degree in genetics at McGill University and his doctoral work in genetics and immunology at Stanford University. Michael was recruited to the Basel Institute for Immunology supported by Hoffman La Roche, where he remained for 13 years. Having published 230 research papers and reviews in his area of expertise, many of which have achieved citation records, Michael has in-depth knowledge of multiple therapeutic areas, including neuroscience, cancer, cardiovascular and immune system; and expertise across multiple platforms, including high content cellular analyses, AI, health informatics, and imaging-guided interventions and therapeutics.